OpGen Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,400.30
749.50
7,814.20
4,117.30
1,847.20
4,572.50
Total Accounts Receivable
241.90
504.00
678.60
542.40
809.50
373.90
Inventories
175.70
369.70
826.00
692.40
533.40
543.70
Other Current Assets
146.40
90.20
566.20
329.60
311.60
292.90
Total Current Assets
1,964.40
1,713.50
9,885.10
5,681.80
3,501.80
5,783
Net Property, Plant & Equipment
1,079.40
588.00
1,074.70
800.70
835.50
1,221.80
Total Investments and Advances
-
-
-
-
243.40
164.70
Intangible Assets
57.60
-
2,526.30
2,221.80
1,954.00
1,686.20
Other Assets
57.50
353.50
270.30
279.80
85.20
94.60
Total Assets
3,158.90
2,654.90
13,756.50
8,984.00
6,619.90
8,950.40
ST Debt & Current Portion LT Debt
116.00
3,105.50
251.80
1,208.20
1,165.80
Accounts Payable
869.20
1,160.10
2,285.80
2,232.60
1,691.70
Other Current Liabilities
1,770.70
1,755.90
2,052.50
1,831.20
1,932.10
Total Current Liabilities
2,755.90
6,021.50
4,590.10
5,271.90
4,789.60
Long-Term Debt
234.60
134.10
1,322.40
146.50
130.20
Other Liabilities
-
-
353.00
398.10
299.20
Total Liabilities
2,990.40
6,155.70
6,265.50
5,816.60
5,218.90
Common Equity (Total)
1,831.40
8,065.60
7,491.00
3,167.50
1,401.00
Total Shareholders' Equity
168.40
3,500.70
7,491.00
3,167.50
1,401.00
Total Equity
168.40
3,500.70
7,491.00
3,167.50
1,401.00
Liabilities & Shareholders' Equity
3,158.90
2,654.90
13,756.50
8,984.00
6,619.90
Preferred Stock (Carrying Value)
1,999.90
4,564.90
-
-
-

About OpGen

View Profile
Address
708 Quince Orchard Road
Gaithersburg Maryland 20878
United States
Employees -
Website http://www.opgen.com
Updated 07/08/2019
OpGen, Inc. operates as a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.